CannPal Animal Therapeutics Ltd (ASX:CP1) continues to demonstrate its leading position in developing unique cannabinoid-based treatment for companion animals by filing a further provisional patent application.
This application, which incorporates results of CannPal’s ongoing research, relates to CPAT-01, the company’s lead drug candidate in development for pain and inflammation control in dogs.
Strengthening company’s IP
The invention relates to a composition comprising a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD).
It builds on an earlier filed provisional patent application for the CPAT-01 formulation and seeks to further strengthen CannPal’s Intellectual Property (IP).
The filing comes hot on the heels of recognition of the company’s extensive research at the 2019 AVA Innovation, Research and Development Symposium in Perth yesterday.
Run by the Australian Veterinary Association, it is Australia’s largest veterinary conference and attracted around 1,400 veterinarians.
CannPal’s head of R&D Dr Margaret Curtis presented on the company’s phase I research results for CPAT-01.
Study results presented
She presented on the pharmacokinetic, safety, gene expression and inflammatory biomarker results from CannPal’s robust randomised three group parallel pharmacokinetic study completed in 2018 for CPAT-01.
Dr Curtis said: “The Innovation Symposium was a fantastic opportunity to showcase the breadth and depth of CannPal’s research to the veterinary fraternity in Australia.
“It was a pleasure to share some of the exciting data that CannPal is generating with the wider scientific community, which we believe can help contribute to the advancement of cannabinoid-derived therapeutic research across all species.”
The research abstract will also reach more than 5,000 through publication in Australia’s premier veterinary scientific journal, the Australian Veterinary Journal.
READ: CannPal Animal Therapeutics sees lucrative opportunity in cannabinoids-based animal health market
CannPal’s founder and managing director Layton Mills said that the presentation and AVJ publication were significant milestones.
“There is significant demand from pet owners for cannabinoid-derived therapeutics, but veterinarians don’t yet have a thought leader providing them with reliable data or regulatory approved products.
“The AVJ publication is the first step in CannPal establishing ourselves as the provider of that data, and hopefully of regulatory approved, safe and effective veterinary medicines.
“This is an important step in building a trusting relationship with vets as we get closer towards commercialising our products through various regulatory pathways.”